Notably, crizotinib (Type I), approved by the FDA in 2011, is primarily used for ALK (anaplastic lymphoma kinase)-positive metastatic non-small cell lung cancer (NSCLC) but also exhibits c-Met inhibitory activity as part of its multi-target mechanism [21,22]. Here, ALK is linked to non-small cell lung carcinoma.